The inversion of chromosome 16 in the inv(16)(p13q22) is one of the most frequent cytogenetic abnormalities observed in acute myeloid leukemia (AML). The inv(16) fuses the core binding factor (CBF) beta subunit with the coiled-coil rod domain of smooth muscle myosin heavy chain (SMMHC). Expression of CBFbeta-SMMHC in mice does not promote AML in the absence of secondary mutations. Patient sampl...

ABSTRACT: The molecular background of canine mast cell tumors (MCT) has been extensively investigated; however, the dynamic changes that occur during carcinogenesis and metastasis are not fully understood. This study aimed to evaluate incidence mutations in c-KIT proto-oncogene MCTs relative draining regional lymph nodes. Suspected or confirmed node was classified accordingly HN Weishaar classi...

Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute myeloid leukemia (AML) and are associated with a poor overall survival. While the normal FLT3 receptor is expressed in early hematopoietic progenitor cells, it has not been determined whether FLT3 mutations are present in the leukemic stem cells. In this study, we sor...

BACKGROUND Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are associated with a poor prognosis. The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concentrations in AML cell lines that harbor FLT3-ITD mutati...

Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently our group and others have shown that pharmacologic inhibition and genetic knockdown of Bruton's ty...

INTRODUCTION In recent years, Fms-like tyrosine kinase (FLT) 3 has been the subject of several studies as a prognostic marker. OBJECTIVE In this study, the presence of FLT3 mutations in childhood acute leukemias patients and their association with prognosis were investigated. MATERIALS AND METHODS A total of 120 patients, 80 with acute lymphoblastic leukemia (ALL) and 40 with acute myelobla...

Objectives The study aims to understand geneome diversi?cation and complexity that developed in Acute myeloid leukemia (AML).Methods Next-generation sequencing (NGS) was used identify the genetic pro?les of 22 genes relevant hematological malignancy 204 patients with de novo non-M3 AML.Results At time initial diagnosis, at least one mutation identified 80.9% (165/204). most commonly mutated gen...

Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myelogenous leukemia (AML) and mutation associated with poor prognosis patients. Two distinct types activating mutations have been identified AML samples. One internal tandem duplications juxtamembrane domain (FLT3-ITD) other point (FLT3-TKD). Gilteritinib a FLT3 inhibitor that inhibits both FLT3-ITD FLT3-TKD...

FLT3-ITD is the most frequent tyrosine kinase mutation in acute myeloid leukemia (AML) associated with poor prognosis. We previously reported that activation of STAT5 confers resistance to PI3K/Akt inhibitors on the FLT3-ITD-positive AML cell line MV4-11 and 32D cells driven by FLT3-ITD (32D/ITD) but not by FLT3 mutated in the tyrosine kinase domain (32D/TKD). Here, we report the involvement of...

We report a case of de novo acute myeloid leukemia (AML) with unstable FLT3 gene mutations and stable NPM1 mutation. FLT3/D835 and NPM1 (Type A) mutations were detected upon diagnosis. During the relapse, the FLT3/D835 mutation changed to an FLT3/ITD mutation while the NPM1 (Type A) mutation was retained. Cytogenetic analyses showed the normal karyotype at diagnosis and relapse. Our findings ra...